Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Upgraded by StockNews.com

StockNews.com upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a hold rating to a buy rating in a research report report published on Friday morning.

TEVA has been the subject of a number of other research reports. Bank of America decreased their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Thursday, March 6th. Barclays reduced their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. UBS Group dropped their target price on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating on the stock in a report on Thursday, January 30th. Finally, Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Trading Down 6.9 %

NYSE TEVA opened at $13.83 on Friday. The firm has a market capitalization of $15.68 billion, a PE ratio of -9.54, a P/E/G ratio of 1.44 and a beta of 0.82. The stock’s 50 day moving average is $16.52 and its 200 day moving average is $18.01. Teva Pharmaceutical Industries has a twelve month low of $12.51 and a twelve month high of $22.80. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. Research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Oarsman Capital Inc. bought a new stake in Teva Pharmaceutical Industries in the 4th quarter worth about $29,000. Marshall & Sterling Wealth Advisors Inc. bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $44,000. Wilmington Savings Fund Society FSB purchased a new position in shares of Teva Pharmaceutical Industries during the third quarter valued at approximately $50,000. Ameliora Wealth Management Ltd. bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $66,000. Finally, Versant Capital Management Inc boosted its holdings in Teva Pharmaceutical Industries by 437.8% in the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company’s stock worth $81,000 after purchasing an additional 4,312 shares during the last quarter. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.